Patient-informed design supported rapid and representative COMPPARE trial accrual
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Tag
prostate
Experts reached limited consensus on prostate GTV contouring and micro-boosting
Only 33% of statements reached consensus, but experts agreed on multimodality imaging, eligible lesions, and daily image guidance.
Adaptive MR-guided prostate SBRT showed low toxicity after the early treatment peak
Grade ≥2 urinary toxicity fell from 22% at two weeks to 3% at six months, with almost no clinically significant bowel toxicity.
Prostate radiotherapy biomarker review found timing more limiting than assay choice
None of four selected blood-biomarker domains currently supports treatment personalization, and sampling schedules frequently failed to match expected biological kinetics.
Virtual reality increased confidence after HDR prostate brachytherapy training
Brief virtual-reality training increased self-reported procedural confidence, but knowledge, technical skill, retention, and clinical performance were not tested.
Five-fraction MR-guided prostate-bed radiotherapy showed low early toxicity
No grade 3 toxicity occurred after five-fraction MR-guided salvage radiotherapy, while urinary and bowel quality-of-life scores remained stable.
Prostate radiotherapy modestly increased secondary pelvic cancer incidence over long follow-up
Randomized evidence suggested a 4.5-point increase in second-cancer incidence, while excess mortality from other cancers was substantially smaller.
AutoAdapt produced acceptable prostate MR-guided plans with minimal planner input
AI-generated constraints produced clinically acceptable adaptive prostate plans, although only seven of ten met every prespecified planning objective.
Prostate focal boost review defines MRI-based contouring and isotoxic planning
MRI-defined biopsy-confirmed lesions can be boosted safely when robust image guidance and normal-tissue constraints take priority over complete boost coverage.
ESTRO defined minimum standards for prostate SBRT implementation
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Five-fraction prostate SBRT showed low severe toxicity across Austrian centres
Linac-based 40 Gy in five fractions produced low severe toxicity and rapid urinary recovery across seven centres, although follow-up remained short.
Biopsy localization uncertainty substantially altered HDR prostate brachytherapy dose estimates
Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
PROTEUS improved composite MFS but not conventional imaging-defined MFS
Perioperative apalutamide improved pathological response and composite MFS, but not conventional imaging-defined MFS, raising concern about overtreatment in broadly defined high-risk disease.
Prolonged first-generation antiandrogens showed no survival benefit with prostate radiotherapy
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Five-fraction prostate radiotherapy showed low severe toxicity in men aged 75 or older
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.